Laronix Inc, a commercial-stage medical technology company involved in voice restoration technologies, and the Greater Baltimore Medical Center (GBMC) announced on Monday the launch of an investigational study of Laronix MIRA Voice to restore voice capabilities for intensive care unit (ICU) patients.

According to Laronix, MIRA Voice has enabled laryngectomy patients with permanent voice loss to generate speech.

This investigational study, to be performed by the multidisciplinary team at Milton J. Dance Jr. Head and Neck Center at GBMC, is designed to assess the efficacy and potential of the device for patients who experience voice loss following tracheostomy or ICU intubation. Results will also serve as developmental feedback for MIRA Voice AI, the next product in Laronix's pipeline, which uses state-of-the-art AI to recreate a patient's original voice.

Involving approximately 12 patients and anticipated to be completed by mid-2026, the study will test the effectiveness of MIRA Voice in enabling patients to express their immediate needs, as well as sustain casual conversation. In addition, the study will measure MIRA Voice improvements to the efficiency and workflow of ICU care teams.